|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
Expression levels of miR-127-3p, miR-133a-3p, miR-155-5p, miR-199b-5p, and miR-342-5p were measured in BC and adjacent normal tissues by RT-qPCR.
|
31595567 |
2020 |
|
Malignant neoplasm of breast
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Overall, we described for the first time the regulatory activity of miR-342-3p on relevant metabolic carcinogenic pathways in TN breast cancers.
|
30115973 |
2018 |
|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
Furthermore, miR-342, miR-520 for triple negative and hormone receptor-positive types of breast cancer, respectively in collaboration with two detected distinct cluster of miRNAs for different breast cancer cell lines can be applied for more dedicated miRNA-based individualized targeted therapy.
|
29243807 |
2018 |
|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
Tamoxifen sensitivity-related microRNA-342 is a useful biomarker for breast cancer survival.
|
29245954 |
2017 |
|
Malignant neoplasm of breast
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
In addition, miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy. miR-146a and miR-146-5p silencing BRCA1 may trigger formation of triple-negative and basal-like sporadic BC cases. miR-182 might effect the therapy outcome. miR-21 targeted therapy might be useful for the treatment of BRCA2 mutation carriers. miR-342 overexpression and the absence of functional BRCA1 gene might cause synthetic lethality, which might be used as a base for future therapies.
|
28128741 |
2017 |
|
Malignant neoplasm of breast
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Together, our findings suggest a tumor-suppressive function of miR-342 that could be exploited in the treatment of a subset of BRCA1-mutant hereditary breast cancers.
|
26919240 |
2016 |
|
Malignant neoplasm of breast
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, higher expression of miR-342-5p was associated with better survival in both breast cancer patient cohorts.
|
24148764 |
2014 |
|
Malignant neoplasm of breast
|
0.390 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of miR-342 in these cells reduced ID4 and increased BRCA1 expression, supporting a possible role of this mechanism in breast cancer.
|
24475217 |
2014 |
|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
BEFREE |
We analyzed the expression of miR-21, miR-205, and miR-342 in 59 patients with breast cancer.
|
22631664 |
2012 |
|
Malignant neoplasm of breast
|
0.390 |
Biomarker
|
disease |
CTD_human |
Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
|
20099276 |
2010 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Expression levels of miR-127-3p, miR-133a-3p, miR-155-5p, miR-199b-5p, and miR-342-5p were measured in BC and adjacent normal tissues by RT-qPCR.
|
31595567 |
2020 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Furthermore, miR-342, miR-520 for triple negative and hormone receptor-positive types of breast cancer, respectively in collaboration with two detected distinct cluster of miRNAs for different breast cancer cell lines can be applied for more dedicated miRNA-based individualized targeted therapy.
|
29243807 |
2018 |
|
Breast Carcinoma
|
0.380 |
GeneticVariation
|
disease |
BEFREE |
In addition, miR-15/107/182-mediated downregulation of BRCA1 interrupt DNA repair and may change the course of BC therapy. miR-146a and miR-146-5p silencing BRCA1 may trigger formation of triple-negative and basal-like sporadic BC cases. miR-182 might effect the therapy outcome. miR-21 targeted therapy might be useful for the treatment of BRCA2 mutation carriers. miR-342 overexpression and the absence of functional BRCA1 gene might cause synthetic lethality, which might be used as a base for future therapies.
|
28128741 |
2017 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Tamoxifen sensitivity-related microRNA-342 is a useful biomarker for breast cancer survival.
|
29245954 |
2017 |
|
Breast Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
miR-342 overexpression results in a synthetic lethal phenotype in BRCA1-mutant HCC1937 breast cancer cells.
|
26919240 |
2016 |
|
Breast Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, higher expression of miR-342-5p was associated with better survival in both breast cancer patient cohorts.
|
24148764 |
2014 |
|
Breast Carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of miR-342 in these cells reduced ID4 and increased BRCA1 expression, supporting a possible role of this mechanism in breast cancer.
|
24475217 |
2014 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
We analyzed the expression of miR-21, miR-205, and miR-342 in 59 patients with breast cancer.
|
22631664 |
2012 |
|
Breast Carcinoma
|
0.380 |
Biomarker
|
disease |
CTD_human |
Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin.
|
20099276 |
2010 |
|
Neoplasm Metastasis
|
0.340 |
AlteredExpression
|
phenotype |
BEFREE |
Low miR-342 expression was associated with distant metastasis and tumor node metastasis stage in patients with NPC.
|
30061949 |
2018 |
|
Neoplasm Metastasis
|
0.340 |
Biomarker
|
phenotype |
BEFREE |
In addition, we observed that Cdc42, a Rho GTPase family member involved in cell proliferation and metastasis, is a direct target of miR‑342‑3p.
|
30106159 |
2018 |
|
Neoplasm Metastasis
|
0.340 |
Biomarker
|
phenotype |
BEFREE |
Bioinformatics analyses demonstrated that SNHG16 might inhibit the interaction between miR-146a-5p and SMAD4, while RP6-24A23.7 might weaken miR-342-3p-EP300 and miR-150-5p-EP300 interactions in metastasis.
|
28299977 |
2017 |
|
Neoplasm Metastasis
|
0.340 |
AlteredExpression
|
phenotype |
BEFREE |
In several different cell lines, lower miR-342 expression results in enhanced proliferation and metastasis potential, both <i>in vitro</i> and in xenogenic transplant conditions.
|
28573106 |
2017 |
|
Neoplasm Metastasis
|
0.340 |
Biomarker
|
phenotype |
CTD_human |
MicroRNA-222 regulates cell invasion by targeting matrix metalloproteinase 1 (MMP1) and manganese superoxide dismutase 2 (SOD2) in tongue squamous cell carcinoma cell lines.
|
19487542 |
2009 |
|
Mammary Neoplasms
|
0.320 |
AlteredExpression
|
group |
BEFREE |
We demonstrated the clinical relevance of the miRNAs and identified miR-342-5p and miR-744* as significantly down-regulated in HER2-positive breast tumors as compared to HER2-negative tumors from two cohorts of breast cancer patients (101 and 1302 cases). miR-342-5p specifically inhibited HER2-positive cell growth, as it had no effect on the growth of HER2-negative control cells in vitro.
|
24148764 |
2014 |